FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response														
1. Name and Address of Reporting Person* WIKLER MATTHEW			2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director 10% Owner						
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302			3. Date of Earliest Transaction (Month/Day/Year) 03/31/2020						Office	r (give title belo	ow)	Other (specify	pelow)		
(Street) BEDMINSTER,, NJ 07921			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City		(State)	(Zip)		Tab	ole I - Noi	ı-Deriva	Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if		3. Transa	ction 4			uired 5. Amor bf (D) Benefic Reporte		ount of Securities cially Owned Following red Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial
				(Month/Day/Ye	ear)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	nd 4)	\ \ \ \ \ \		Ownership (Instr. 4)
G	Stock		03/31/2020			A		26,450	A	\$ 0	189,568			D	
Common		separate line for	each class of secur	ities beneficially	owi		ly or inc	directly. ns who ned in t	this for	m are	not requ	ction of inf	spond unl	ess	1474 (9-02)
		separate line for	Table II - I	Derivative Secu	ritie	es Acquire	ly or inc Persor contain the for	directly. ns who ned in to	this for lays a c	m are curren	not requ itly valid	uired to res	spond unl	ess	1474 (9-02)
Reminder: 1. Title of Derivative Security	Report on a s	3. Transaction Date (Month/Day/Y	Table II - I (3A. Deemed Execution Date any	,	ritie war 5 N 0 E S A (A	es Acquire rrants, op	ly or inc Persor contain the for ed, Disp tions, co	directly. ns who ned in to	this formal and the security of the security o	eficiall ities) 7. Tit Amo Under Security	not required to the and the and the and the erlying	OMB conf	spond unl	of 10. Owners Form o Derivat Security Direct (or Indir	11. Nath

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
WIKLER MATTHEW C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER,, NJ 07921	X				

Signatures

/s/_Keith A. Kucinski, attorney-in fact for Matthew Wikler	04/02/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 31, 2020, the Reporting Person was issued 26,450 shares of common stock par value \$.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.